A comprehensive systematic review has revealed that teleretinal screening demonstrates high diagnostic accuracy for detecting cytomegalovirus retinitis (CMVR) in people living with HIV, offering a promising solution for preventing blindness in resource-limited settings. The meta-analysis, published in PLOS Global Public Health, analyzed data from five studies encompassing 1,460 eyes to establish the first comprehensive evidence base for this diagnostic approach.
Teleretinal Screening Performance for Cytomegalovirus Retinitis
Diagnostic accuracy measures from meta-analysis of 5 studies, 1,460 eyes
Source: Uy et al., PLOS Global Public Health, 2025 | Georgian Medical Journal News
Critical Gap in HIV Eye Care Access
Cytomegalovirus retinitis remains a leading cause of preventable blindness among people living with HIV, particularly affecting those with severely compromised immune systems, according to the research team led by Holijah Uy and colleagues in their PLOS Global Public Health study. The study notes that CMVR disproportionately impacts patients in resource-limited settings where access to specialized ophthalmological care is severely constrained.
Traditional diagnosis requires direct examination by ophthalmologists using fundoscopy, a resource often unavailable in many healthcare systems serving HIV populations, according to the Uy et al. study.
This accessibility challenge has created an urgent need for alternative diagnostic approaches, as noted by the researchers in their PLOS Global Public Health publication.
Robust Evidence from Multiple Settings
The systematic review, conducted according to PRISMA diagnostic test accuracy guidelines and registered in PROSPERO (CRD420250637110), analyzed studies from diverse healthcare settings to establish comprehensive diagnostic parameters. The meta-analysis employed the hierarchical summary receiver operating characteristic (HSROC) model to pool sensitivity and specificity values across included studies, as detailed in the Uy et al. methodology.
Risk of bias assessment using the QUADAS-2 tool revealed generally high methodological quality among included studies, according to the researchers. The study authors conducted sensitivity analyses that showed no significant changes in diagnostic accuracy after excluding studies with higher risk of bias.
Subgroup analyses revealed particularly promising results among populations with lower CD4 cell count thresholds, according to the Uy et al. findings. The researchers note this finding aligns with the pathophysiology of CMVR, which typically manifests in patients with advanced immunosuppression.
Technology Enabling Decentralized Care
The Uy et al. study examined various fundus imaging modalities used in teleretinal screening programs across different country income settings. Results demonstrated consistently high specificity across different technological approaches, according to their analysis.
Quality of evidence assessment using the GRADE framework rated the specificity evidence as high-certainty, while sensitivity evidence received a low-certainty rating due to wider confidence intervals, as reported by Uy and colleagues.
Implementation Considerations for Healthcare Systems
The research findings carry significant implications for healthcare policy and resource allocation in HIV care programs. The high specificity rate of 97.73% means that positive screening results are highly reliable, reducing unnecessary referrals and optimizing specialist resources, according to the study authors.
However, the sensitivity rate of 87.11%, while clinically useful, indicates that approximately 13% of CMVR cases might be missed by teleretinal screening alone, as noted in the Uy et al. analysis. This limitation necessitates careful consideration of screening protocols and follow-up strategies, particularly for patients with very low CD4 counts who face highest risk.
The study authors concluded that “teleretinal screening for CMVR demonstrates consistently high specificity and potentially useful sensitivity, supporting its role in early detection and referral, particularly among PLHIV with advanced HIV disease.”
— Uy et al., PLOS Global Public Health, 2025
Key takeaways
- Teleretinal screening achieves 97.73% specificity and 87.11% sensitivity for CMVR detection in HIV patients (Uy et al., 2025)
- Diagnostic performance appears enhanced among populations with lower CD4 cell counts (Uy et al., 2025)
- High specificity ensures reliable positive results, optimizing specialist referral resources
- Technology offers scalable solution for resource-limited settings lacking ophthalmologist access
Frequently asked questions
What is cytomegalovirus retinitis and why is it dangerous for HIV patients?
Cytomegalovirus retinitis (CMVR) is a viral infection of the retina that can cause irreversible blindness if untreated. According to the Uy et al. study, it primarily affects people living with HIV who have severely compromised immune systems.
How does teleretinal screening work for CMVR detection?
Teleretinal screening uses digital fundus photography to capture images of the retina, which are then transmitted to specialists for remote interpretation. This approach eliminates the need for patients to travel to specialized ophthalmology centers for initial screening.
What do the sensitivity and specificity rates mean for patients?
The 97.73% specificity means that if the test is positive, there’s a very high chance the patient actually has CMVR. The 87.11% sensitivity indicates that the test correctly identifies about 87 out of 100 people who have the condition, missing approximately 13%, according to the Uy et al. findings.
The integration of teleretinal screening into routine HIV care represents a significant advancement in preventing avoidable blindness among vulnerable populations, according to the study authors. Future research should focus on real-world implementation studies and long-term patient outcomes to fully establish the clinical and economic value of this diagnostic approach.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
